Common Stock, par value $.0001 per share
- Symbol
- XAIR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 7.01, 9.01 · 8-K
Beyond Air, Inc.
XAIRNASDAQEQUITYCurrent
Results of Operations and Financial Condition · Regulation FD Disclosure
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. ─────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release from Beyond Air, Inc., dated as of October 8, 2026. 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
Press release in this filing
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 →Recent company filings
- Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 24, 2026
- EFFECT filingAug 24, 2026
- 424B3 filingAug 24, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureAug 18, 2026
- S-3 filingAug 17, 2026
Registered securities in this filing
Beyond Air, Inc. · 8-K · Filed 2026-10-08
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit Description
No.
───────────────────────────────────────────────────────────────────────────────────────
99.1 Press Release from Beyond Air, Inc., dated as of October 8, 2026.
104 Cover
Page Interactive Data File (embedded within the inline XBRL document).
Filed exhibits (1)
Exhibit 99.1 Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year Performance reflects continued adoption for first-generation LungFit PH; second-generation system remains under FDA review Reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 GARDEN CITY, N.Y., October 8, 2026 - Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026. The preliminary revenue represents an increase of approximately 30% compared with the quarter ended June 30, 2026 and 27% compared with the same quarter last year, and reflects the successful rollout of the Company’s enhanced commercial execution strategy for LungFit PH. “Our strong revenue growth in the quarter ended September 30, 2026 r…
Open exhibit ↗